Amneal Pharmaceuticals 관리

관리 기준 확인 4/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Chirag Patel

최고 경영자

US$2.4m

총 보상

CEO 급여 비율	31.6%
CEO 임기	20yrs
CEO 소유권	7.0%
경영진 평균 재임 기간	5.5yrs
이사회 평균 재임 기간	6.7yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Chirag Patel 의 보수는 Amneal Pharmaceuticals 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	-US$184m
Jun 30 2024	n/a	n/a	-US$175m
Mar 31 2024	n/a	n/a	-US$169m
Dec 31 2023	US$2m	US$750k	-US$84m
Sep 30 2023	n/a	n/a	US$10m
Jun 30 2023	n/a	n/a	-US$2m
Mar 31 2023	n/a	n/a	-US$135m
Dec 31 2022	US$5m	US$750k	-US$130m
Sep 30 2022	n/a	n/a	-US$132m
Jun 30 2022	n/a	n/a	-US$134m
Mar 31 2022	n/a	n/a	US$2m
Dec 31 2021	US$5m	US$724k	US$11m
Sep 30 2021	n/a	n/a	US$14m
Jun 30 2021	n/a	n/a	US$9m
Mar 31 2021	n/a	n/a	-US$17m
Dec 31 2020	US$2m	US$1	US$91m
Sep 30 2020	n/a	n/a	US$62m
Jun 30 2020	n/a	n/a	-US$194m
Mar 31 2020	n/a	n/a	-US$199m
Dec 31 2019	US$446k	US$44k	-US$362m
Sep 30 2019	n/a	n/a	-US$339m
Jun 30 2019	n/a	n/a	-US$67m
Mar 31 2019	n/a	n/a	-US$69m
Dec 31 2018	US$325k	n/a	-US$21m

보상 대 시장: Chirag 의 총 보상 ($USD 2.37M )은 German 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 2.23M ).

보상과 수익: Chirag 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Chirag Patel (57 yo)

20yrs

테뉴어

US$2,370,385

보상

Mr. Chirag K. Patel has been Co-Chief Executive Officer, President and Director of Amneal Pharmaceuticals, Inc. since August 3, 2019. Mr. Patel Co-founded Amneal Pharmaceuticals LLC in 2005 and serves as D...

리더십 팀

이름	위치	테뉴어	보상	소유권
Chirag Patel	Co-Founder	20yrs	US$2.37m	7.03% € 165.9m
Chintu Patel	Co-Founder	23yrs	US$2.37m	8.15% € 192.5m
Anastasios Konidaris	Executive VP & CFO	4.8yrs	US$1.89m	0.17% € 4.0m
Jason Daly	Senior VP	3yrs	US$1.35m	0% € 0
Nikita Shah	Executive VP & Chief Human Resources Officer	11yrs	US$1.53m	0.094% € 2.2m
Andrew Boyer	Executive VP & Chief Commercial Officer of Generics	6.9yrs	US$1.94m	0.083% € 2.0m
Anthony DiMeo	Head of Investor Relations	no data	데이터 없음	데이터 없음
Gregory Sgammato	Senior Vice President of Corporate Development	2yrs	데이터 없음	데이터 없음
Pranav Mehta	Senior VP of Strategic Sourcing & Supply Management	2yrs	데이터 없음	데이터 없음
Sanjay Jain	Chief Quality Officer	6yrs	데이터 없음	데이터 없음
Srinivas Kone	Senior VP & Chief Scientific Officer of Generics	5yrs	데이터 없음	데이터 없음
Stanley Fisher	Vice President & Head of Medical Affairs	no data	데이터 없음	데이터 없음

5.5yrs

평균 재임 기간

54.5yo

평균 연령

경험이 풍부한 관리: 2DT 의 관리팀은 노련하고 경험 (평균 재직 기간 5.5 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Chirag Patel	Co-Founder	20yrs	US$2.37m	7.03% € 165.9m
Chintu Patel	Co-Founder	23yrs	US$2.37m	8.15% € 192.5m
Paul Meister	Independent Chairman of the Board	5.4yrs	US$299.08k	0.23% € 5.5m
J. Buchi	Independent Director	6.7yrs	US$302.20k	0.085% € 2.0m
Ted Nark	Independent Director	6.7yrs	US$244.70k	0.097% € 2.3m
Shlomo Yanai	Independent Director	5.1yrs	US$254.70k	0.079% € 1.9m
Jeffrey George	Independent Director	5.1yrs	US$277.20k	0.087% € 2.1m
Gautam Patel	Director	6.7yrs	US$217.20k	0.64% € 15.0m
Deborah Autor	Independent Director	2.5yrs	US$267.04k	0.017% € 407.0k
Emily Alva	Independent Director	6.7yrs	US$217.20k	0.081% € 1.9m
John Kiely	Independent Director	5.1yrs	US$284.70k	0.086% € 2.0m

6.7yrs

평균 재임 기간

57yo

평균 연령

경험이 풍부한 이사회: 2DT 의 이사회는 경험(평균 재직 기간 6.7 년)으로 간주됩니다.

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2025/01/15 10:28
장 마감 주가	2025/01/14 00:00
수익	2024/09/30
연간 수익	2023/12/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.

애널리스트 출처

Amneal Pharmaceuticals, Inc. 20 애널리스트 중 3 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Balaji Prasad	Barclays
Balaji Prasad	Barclays
Gary Nachman	BMO Capital Markets Equity Research

Amneal Pharmaceuticals 관리

관리 기준 확인 4/4

주요 정보

최근 관리 업데이트

Insufficient new directors

Insider recently sold €703k worth of stock

Independent Director recently sold €236k worth of stock

Amneal Pharmaceuticals, Inc., Annual General Meeting, May 02, 2024

Insufficient new directors

Insufficient new directors

Recent updates

Insufficient new directors

Amneal Pharmaceuticals, Inc. Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist

Third quarter 2024 earnings released: US$0.001 loss per share (vs US$0.063 profit in 3Q 2023)

Amneal Pharmaceuticals, Inc. Affirms Earnings Guidance for the Full Year 2024

New major risk - Shareholder dilution

Amneal Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 08, 2024

Amneal Pharmaceuticals, Inc. Receives U.S. FDA Approval for Propofol Injectable Emulsion Single Dose Vials

Insider recently sold €703k worth of stock

Second quarter 2024 earnings released: EPS: US$0.019 (vs US$0.078 in 2Q 2023)

Amneal Pharmaceuticals, Inc. Raises Earnings Guidance for the Full Year 2024

Amneal Receives U.S. FDA Approval for IPX203 for Treatment of Parkinson’s Disease to Be Launched as CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules

Amneal Pharmaceuticals, Inc. Receives U.S. FDA Approval for Potassium Phosphates Injection IV Bags

Amneal Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 09, 2024

Amneal Pharmaceuticals, Inc. Launches FOCINVEZ, the First Ready-to-Use Version of Fosaprepitant

Amneal Pharmaceuticals, Inc. Expands Biosimilars Portfolio to Eight Products with Addition of Omalizumab Biosimilar

Amneal Pharmaceuticals, Inc. Expands Broad Injectables Portfolio to over 40 Products with the Addition of Six New Therapies

Independent Director recently sold €236k worth of stock

First quarter 2024 earnings released: US$0.30 loss per share (vs US$0.046 loss in 1Q 2023)

Amneal Announces U.S. FDA Approval of Over-The-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid Overdose

Amneal Pharmaceuticals Announces Launch of Pemetrexed Injection, 100mg/10 Mg/10 Mg/50 Mg/Ll (NDA)

Amneal Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 03, 2024

Amneal Pharmaceuticals, Inc., Annual General Meeting, May 02, 2024

Full year 2023 earnings released: US$0.48 loss per share (vs US$0.86 loss in FY 2022)

Amneal Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2024

Amneal Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 01, 2024

Amneal Pharmaceuticals, Inc. Announces the Approval and Launch of Fluorometholone Ophthalmic Suspension

Third quarter 2023 earnings released: EPS: US$0.063 (vs US$0.018 loss in 3Q 2022)

Amneal Pharmaceuticals, Inc. Revises Earnings Guidance for the Year Ending December 31, 2023

Amneal Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Amneal Pharmaceuticals, Inc. Receives U.S. Fda Approval for Calcium Gluconate Injection

Amneal Pharmaceuticals, Inc. Publishes Phase 3 Study Results Comparing Ipx203 to Immediate-Release Carbidopa/Levodopa for Parkinson's Disease

Second quarter 2023 earnings released: EPS: US$0.078 (vs US$0.80 loss in 2Q 2022)

Amneal Pharmaceuticals, Inc. Raises Revenue Guidance for the Full Year 2023

Amneal Pharmaceuticals, Inc. Submits Abbreviated New Drug Applications to U.S. FDA for Three Key Complex Generics

Amneal Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 04, 2023

Amneal Launches Authorized Generic for Xyrem® (Sodium Oxybate) and Receives FDA Approval for Five Complex Generics in the Second Quarter

Amneal Receives 505(B)(2) Nda Approval from FDA for PEMRYDI RTU, A Ready-To-Use Oncology Injectable

Amneal Pharmaceuticals, Inc. Launches Third Biosimilar with FYLNETRA™? (pegfilgrastim-pbbk) in the United States

First quarter 2023 earnings released: US$0.046 loss per share (vs US$0.014 loss in 1Q 2022)

Insufficient new directors

First quarter 2023 earnings released: US$0.046 loss per share (vs US$0.014 loss in 1Q 2022)

Amneal Pharmaceuticals, Inc. Reaffirms Earnings Guidance for the Year 2023

Full year 2022 earnings released: US$0.86 loss per share (vs US$0.071 profit in FY 2021)

Amneal Pharmaceuticals, Inc. to Report Q4, 2022 Results on Mar 02, 2023

Insufficient new directors

Insufficient new directors

Amneal Pharmaceuticals, Inc. Announces 26 Generic New Product Launches in 2022 and First Injection Large Volume Bag Approval

Amneal Launches Second Biosimilar with RELEUKO® (filgrastim-ayow) in the United States

Amneal Pharmaceuticals, Inc. Announces U.S. FDA Filing Acceptance of New Drug Application for IPX203 for the Treatment of Parkinson’s Disease

Third quarter 2022 earnings released: US$0.018 loss per share (vs US$0.028 loss in 3Q 2021)

Amneal Pharmaceuticals, Inc. Announces Impairment Charges for the Third Quarter Ended September 30, 2022

Amneal Pharmaceuticals, Inc. Receives FDA Approval for Leuprolide Acetate Injection

Amneal Pharmaceuticals, Inc. Announces Management Changes

Amneal Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 04, 2022

Amneal Pharmaceuticals, Inc. Announces the Commercial Launch of ALYMSYS

Amneal Pharmaceuticals, Inc. Appoints Gustavo Pesquin as Executive Vice President, Chief Commercial Officer - Specialty

Amneal Pharmaceuticals, Inc. Announces Submission of New Drug Application to the U.S. FDA for IPX203 for the Treatment of Parkinson’s Disease

Amneal Pharmaceuticals, Inc. Launches 4 New Generic Products, Including Vasopressin Single-Dose

Second quarter 2022 earnings released: US$0.80 loss per share (vs US$0.098 profit in 2Q 2021)

Amneal Pharmaceuticals, Inc. Updates Earnings Guidance for the Full Year 2022

High number of new directors

Amneal Pharmaceuticals, Inc. Appoints Deborah M. Autor to Board of Directors

Amneal Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 05, 2022

Amneal Pharmaceuticals, Inc. Announces Class Action Lawsuit Settlement Updates

Amneal Pharmaceuticals, Inc. Launches LYVISPAH for Spasticity Related to Multiple Sclerosis and Other Spinal Cord Disorders

Amneal Achieves Third U.S. Biosimilar Approval with FYLNETRA™ (pegfilgrastim-pbbk)

First quarter 2022 earnings released: US$0.014 loss per share (vs US$0.045 profit in 1Q 2021)

Amneal Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2022

Amneal Achieves Second U.S. Biosimilars Approval with ALYMSYS® (bevacizumab-maly)